Pharmacokinetics of cannabichromene in a medical cannabis product also containing cannabidiol and Δ
Cannabichromene
Cannabis
Pharmacokinetics
Phytocannabinoid
Journal
European journal of clinical pharmacology
ISSN: 1432-1041
Titre abrégé: Eur J Clin Pharmacol
Pays: Germany
ID NLM: 1256165
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
28
04
2021
accepted:
11
10
2021
pubmed:
20
10
2021
medline:
26
2
2022
entrez:
19
10
2021
Statut:
ppublish
Résumé
Cannabichromene (CBC) is a phytocannabinoid commonly found in cannabis, yet its acute post-dose pharmacokinetics (PK) have not been examined in humans. This is a secondary data analysis from a trial investigating Spectrum Yellow oil, an oral cannabis product used for medical purposes that contained 20 mg cannabidiol (CBD), 0.9 mg Δ Participants (N = 43) were randomized to one of 5 groups: 120 mg CBD, 5.4 mg THC, and 6.6 mg CBC daily; 240 mg CBD, 10.8 mg THC, and 13.2 mg CBC daily; 360 mg CBD, 16.2 mg THC, and 19.8 mg CBC daily; 480 mg CBD, 21.6 mg THC, and 26.4 mg CBC daily; or placebo. Study medication was administered every 12 h for 7 days. Plasma CBC concentrations were analyzed by a validated two-dimensional high-performance liquid chromatography-tandem mass spectrometry assay. After a single dose and after the final dose, the C CBC may have preferential absorption over CBD and THC when administered together. Australian New Zealand Clinical Trials Registry #ACTRN12619001450101, registered 18 October 2019.
Identifiants
pubmed: 34664109
doi: 10.1007/s00228-021-03232-8
pii: 10.1007/s00228-021-03232-8
pmc: PMC8748343
doi:
Substances chimiques
Cannabinoids
0
Medical Marijuana
0
Cannabidiol
19GBJ60SN5
Dronabinol
7J8897W37S
cannabichromene
K4497H250W
Types de publication
Clinical Trial, Phase I
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
259-265Informations de copyright
© 2021. The Author(s).
Références
Trends Pharmacol Sci. 2009 Oct;30(10):515-27
pubmed: 19729208
Neurosci Biobehav Rev. 2019 Dec;107:696-712
pubmed: 31580839
Gen Pharmacol. 1983;14(2):247-52
pubmed: 6301931
Drug Alcohol Depend. 2010 Nov 1;112(1-2):126-33
pubmed: 20619971
Neurotoxicol Teratol. 2014 Nov-Dec;46:49-56
pubmed: 25311884
Ther Drug Monit. 2017 Oct;39(5):556-564
pubmed: 28640062
PLoS One. 2013 Jul 24;8(7):e70052
pubmed: 23894589
Psychopharmacology (Berl). 2019 Sep;236(9):2713-2724
pubmed: 31044290
Br J Pharmacol. 2011 Feb;162(3):584-96
pubmed: 20942863
J Anal Toxicol. 2021 Mar 12;:
pubmed: 33710277
Br J Pharmacol. 2011 Aug;163(7):1479-94
pubmed: 21175579
J Pharmacol Exp Ther. 2008 Jun;325(3):1007-15
pubmed: 18354058
Br J Pharmacol. 2012 Jun;166(4):1444-60
pubmed: 22300105
Ther Drug Monit. 2005 Dec;27(6):799-810
pubmed: 16306858
Fitoterapia. 2010 Oct;81(7):816-9
pubmed: 20450962
Br J Pharmacol. 2019 Dec;176(23):4537-4547
pubmed: 31368508
J Forensic Sci. 2010 Sep;55(5):1209-17
pubmed: 20487147
J Clin Pharmacol. 1981 Aug-Sep;21(S1):283S-291S
pubmed: 7298870
JAMA. 2019 Sep 10;322(10):974-975
pubmed: 31397842
J Forensic Sci. 2008 Jan;53(1):90-4
pubmed: 18279244
J Pharmacol Exp Ther. 2006 Sep;318(3):1375-87
pubmed: 16728591
Front Neurol. 2019 Jul 03;10:716
pubmed: 31333569
Pharmacol Biochem Behav. 2010 Jun;95(4):434-42
pubmed: 20332000
J Nat Prod. 1980 Mar-Apr;43(2):169-234
pubmed: 6991645
Neurochem Int. 2013 Nov;63(5):432-7
pubmed: 23941747
Br J Pharmacol. 2013 May;169(1):213-29
pubmed: 23373571
J Nat Prod. 2008 Aug;71(8):1427-30
pubmed: 18681481